Konruns Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 95.72 million yuan, up 5.1% year on year. Operating revenue was 463 million yuan, up 0.4% year on year, while net profit attributable to the parent after deducting non-recurring items was 92.18 million yuan, down 4.2% year on year. Second-quarter net profit attributable to the parent was 48.51 million yuan, up 4.2% year on year. Research and development spending was 64.98 million yuan, up 29.03% year on year, and the marketing registration application for its core pipeline candidate ZY5301 was accepted in April 2026.
Beijing Konruns Pharmaceutical Co LtdNet profit up 5.1% but core profit down 4.2%; R&D spending up 29% and ZY5301 application accepted.
